Cancer prevention: Strong science and real medicine

Journal of Clinical Oncology

Volumn 23, Issue 2, 2005, Pages 249-253

  Lippman, Scott M ^a   Levin, Bernard ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CALCIUM; CELECOXIB; FINASTERIDE; HEPATITIS VACCINE; SELENIUM; SULINDAC; TAMOXIFEN; VACCINE;

ADENOMATOUS POLYP; ADJUVANT THERAPY; BREAST CANCER; CANCER GENETICS; CANCER PREVENTION; CANCER RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; EDITORIAL; HEALTH BEHAVIOR; HUMAN; LIVER CANCER; MEDICAL LITERATURE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; UTERINE CERVIX CANCER; DRUG DELIVERY SYSTEM; NEOPLASM; NUTRITION; OBESITY; PHARMACEUTICS; RESEARCH; SMOKING;

DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; NUTRITION PHYSIOLOGY; OBESITY; RANDOMIZED CONTROLLED TRIALS; RESEARCH; SMOKING; TECHNOLOGY, PHARMACEUTICAL;

EID: 13744262317     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.10.071     Document Type: Editorial

References (57)

1. Jemal A, Tiwari RC, Murray T, et al: Cancer statistics, 2004. CA Cancer J Clin 54:8-29, 2004
2. Lippman SM, Hong WK: Cancer prevention science and practice. Cancer Res 62:5119-5125, 2002
3. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
4. Thompson IM, Goodman PJ, Tangen CM, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 349:215-224, 2003
5. Moon TE, Levin N, Cartmel B, et al: Effect of retinol in preventing squamous cell skin cancer in moderate-risk subjects: A randomized, double-blind, controlled trial. Cancer Epidemiol Biomarkers Prev 6:949-956, 1997
6. Steinbach G, Lynch PM, Phillips RK, et al: The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342:1946-1952, 2000
7. Baron JA, Beach M, Mandel JS, et al: Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 340:101-107, 1999
8. Baron JA, Cole BF, Sandler RS, et al: A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348:891-899, 2003
9. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al: Treatment and prevention of intraepithelial neoplasia: An important target for accelerated new agent development. Clin Cancer Res 8:314-346, 2002
10. Weitzel JN, McCahill LE: The power of genetics to target surgical prevention. N Engl J Med 344:1942-1944, 2001
11. Traverse G, Shuber A, Levin B, et al: Detection of APC mutations in fecal DNA of patients with colorectal tumors. N Engl J Med 346:311-320, 2002
12. Lippman SM, Hong WK: Molecular markers of the risk of oral cancer. N Engl J Med 34:1323-1326, 2001
13. Lippman SM, Goodman PJ, Klein EA, et al: Designing the selenium and vitamin E cancer prevention trial (SELECT). J Natl Cancer Inst: (in press)
14. Viner JL, Hawk E, Lippman SM: Cancer chemoprevention, In Schottenfeld D, Fraumeni J (eds): Cancer epidemiology and prevention (in press)
15. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med 330:1029-1035, 1994
16. Ommen GS, Goodman GE, Thornquist MD, et al: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334:1150-1155, 1996
17. Vineis P, Alavanja M, Buffler P, et al: Tobacco and cancer: Recent epidemiological evidence. J Natl Cancer Inst 96:99-106, 2004
18. Lerman C, Berrettini W: Elucidating the role of genetic factors in smoking behavior and nicotine dependence. Am J Med Genet 1186:48-54, 2003
19. Calle EE, Thun MJ: Obesity and cancer. Oncogene 23:6365-6378, 2004
20. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 336:1855-1859, 1997
21. Wands JR: Prevention of hepatocellular carcinoma. N Engl J Med 351:1567-1570, 2004
22. Koutsky LA, Ault K, Wheeler CM, et al: A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347:1645-1651, 2002
23. Mao L, Hong WK: How does papillomavirus contribute to head and neck cancer development? J Natl Cancer Inst 96:978-980, 2004
24. Sutton P, Doidge C: Helicobacter pylori vaccines spiral into the new millennium. Dig Liver Dis 35:675-687, 2003
25. Fahey JW, Haristoy X, Dolan PM, et al: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Heiicobacter pylori and prevents benzo[z]pyrene-mduced stomach tumors. Proc Natl Acad Sci U S A 99:7610-7615, 2002
26. Basset C, Holton J, Gatta L, et al: Heiicobacter pylori infection: Anything new should we know? Aliment Pharmacol Ther 20:31-41, 2004 (suppl 2)
27. Thompson IM, Pauler DK, Goodman PJ, et al: Prevalence of prostate cancer among men with prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239-2246, 2004
28. Stamey TA, Caldwell M, McNeal JE, et al: The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol 172:1297-1301, 2004
29. Aleman M, Karakiewicz PI, Kupelian P, et al: Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: Implications for screening. Urology 62:70-74, 2003
30. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319:525-532, 1988
31. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100:57-70, 2000
32. Taylor PR, Parnes HL, Lippman SM: Science peels the onion of selenium effects on prostate carcinogenesis. J Natl Cancer Inst 96:645-647, 2004
33. Yu MK, Moos PJ, Cassidy P, et al: Conditional expression of 15-lipoxygenase-1 inhibits the selenoenzyme thioredoxin reductase: Modulation of selenoproteins by lipoxygenase enzymes. J Biol Chem 279:28028-28035, 2004
34. Shureiqi I, Jiang W, Zuo X, et al: The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells. Proc Natl Acad Sci U S A 100:9968-9973, 2003
35. Pai R, Soreghan B, Szabo IL, et al: Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med 8:289-293, 2002
36. Wang D, Wang H, Shi Q, et al: Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6:285-295, 2004
37. Salas TR, Kim J, Vakar-Lopez F, et al: Glycogen synthase kinase-3β is involved in the phosphorylation and suppression of androgen receptor activity. J Biol Chem 279:19191-19200, 2004
38. Wang L, Lin H-K, Hu Y-C, et al: Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3/3 in prostate cells. J Biol Chem 279:32444-32452, 2004
39. Hull MA, Ko SCW, Hawcroft G: Prostaglandin EP receptors: Targets for treatments and prevention of colorectal cancer? Molec Cancer Ther 3:1031-1039, 2004
40. Majumder PKL, Febbo PG, Bikoff R, et al: mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10:594-601, 2004
41. Hay N, Sonenberg N: Upstream and downstream of mTOR. Genes Dev 18:1926-1945, 2004
42. Mahmood U, Weissleder R: Near-infrared optical imaging of proteases in cancer. Molec Cancer Ther 2:489-496, 2003
43. Pollak MN, Shernhammer ES, Hankinson SE: Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505-518, 2004
44. Clevers H: At the crossroads of inflammation and cancer. Cell 118:671-674, 2004
45. Xiao Z, Luke BT, Izmirlian G, et al: Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 64:2904-2909, 2004
46. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al: An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. J Clin Oncol 21:4546-4552, 2003
47. Hsi LC, Xi X, Lotan R, et al: The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells. Cancer Res 64:8778-8781, 2004
48. Sudbo J, Lippman SM, Lee JJ, et al: The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med 350:1405-1413, 2004
49. Keller JJ, Offerhaus GJA, Drillenburg P, et al: Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis. Clin Cancer Res 7:4000-4007, 2001
50. Hisamuddin IM, Wehbi MA, Chao A, et al: Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis. Clin Cancer Res: in press
51. Makridakis NM, Ross RK, Pike MC, et al: Association of missense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet 354:975-978, 1999
52. Makridakis N, Akalu A, Reichardt JKV: Identification and characterization of somatic steroid 5α-reductase (SRD5A2) mutations in human prostate cancer tissue. Oncogene 23:7399-7405, 2004
53. Abbruzzese JL, Lippman SM: The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 6:321-326, 2004
54. Lippman SM, Brown PH: Tamoxifen prevention of breast cancer: An instance of the fingerpost. J Natl Cancer Inst 91:1809-1819, 1999
55. Swain SM, Wilson JW, Mamounas EP, et al: Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 96:516-523, 2004
56. von Eschenbach AC: Opinion: A vision for the national cancer program in the United States. Nat Rev Cancer 4:820-828, 2004
57. Lippman SM, Levin B, Brenner DE, et al: Cancer prevention and the American Society of Clinical Oncology. J Clin Oncol 22:3848-3851, 2004